RemeGen Co., Ltd. Announces Multiple Purchases of Wealth Management Products
RemeGen Co., Ltd. (Stock Code: 9995), a biopharmaceutical company listed in Hong Kong and Shanghai, has announced a series of substantial investments in wealth management products, totaling RMB 598 million within a short span in May 2026. These transactions constitute a discloseable transaction under Chapter 14 of the Hong Kong Listing Rules, which could be significant for shareholders and investors.
Key Points for Investors
- Board Approval: The Board authorized the use of up to RMB 2,500 million of idle self-owned funds for cash management and wealth management product purchases.
- Transaction Details: Between May 14 and May 26, 2026, RemeGen entered into nine separate agreements with Huatai Securities Co., Ltd. (HTSC) for the purchase of wealth management products. The aggregate amount invested is RMB 598 million.
- Product Information: The latest agreement (No. 9) involves RMB 60 million invested in the Zijin Trust • Gu’an Xinliangjin No. 1 Collective Fund Trust Plan, a fixed-income collective fund trust with a 10-year duration and a 6-month lock-up period, after which redemption is possible. The risk rating is low-to-medium, and the investment scope includes cash-type assets and fixed-income assets. The yield is expected to be higher than bank deposits but subject to market fluctuations.
- Listing Rules Implications: Since these transactions are with the same financial institution (HTSC) and of similar nature within 12 months, the percentage ratios are aggregated. The cumulative ratio exceeds 5% but remains below 25%, triggering a discloseable transaction status. This means the company must report and announce these under the Listing Rules.
Significance for Shareholders and Potential Price Sensitivity
- Capital Utilization: RemeGen aims to optimize idle funds and boost returns, with the Directors considering the terms to be fair, reasonable, and beneficial to the company and shareholders.
- Risk Management: The company stresses strict risk control, with products chosen for controllable risks and yields superior to traditional deposits.
- Transparency: All agreements were negotiated at arm’s length, and HTSC and its major shareholders are independent third parties, minimizing conflict-of-interest concerns.
- Potential Share Price Impact: The large-scale deployment of capital to wealth management products could affect liquidity, risk profile, and capital structure, which may be price sensitive. The move signals confidence in the company’s financial position and ability to generate higher returns, which could positively influence investor sentiment.
Background on Parties
- RemeGen: A commercial-ready biopharmaceutical firm focused on innovative biologics for autoimmune, oncology, and ophthalmic diseases.
- HTSC: A major securities company listed in Shanghai and Hong Kong, offering financial services including wealth management and investment management.
Summary of Agreements
- May 14, 2026: Agreements No. 1-4 (RMB 60m, RMB 75m, RMB 102m, RMB 216m)
- May 19, 2026: Agreements No. 5-6 (RMB 15m, RMB 20m)
- May 20, 2026: Agreements No. 7-8 (RMB 20m, RMB 30m)
- May 26, 2026: Agreement No. 9 (RMB 60m)
Important Definitions
- Discloseable Transaction: A transaction which triggers mandatory reporting and announcement requirements under the Listing Rules due to its size relative to the company’s assets.
- Connected Person: As defined under the Listing Rules, but HTSC is confirmed as an independent third party.
Board Composition
The Board comprises a mix of executive, non-executive, and independent non-executive directors, with Mr. Wang Weidong serving as Chairman.
Conclusion
RemeGen’s aggressive deployment of idle funds into wealth management products, with a clear focus on risk control and yield optimization, is a significant capital move. The aggregated transactions surpass the 5% threshold under Listing Rules, making this a discloseable event. Investors should monitor the company’s liquidity and risk management closely, as this could impact future earnings and share price.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. The information presented is based on publicly disclosed announcements and may be subject to change or interpretation.
【廣東話版本】
RemeGen股份有限公司公佈重大財務交易：購買理財產品詳情
RemeGen股份有限公司（股份代號：9995），於2026年5月短短數日內，宣布以自有閒置資金購買理財產品，合共投資人民幣5.98億元，屬香港上市規則下之「須披露交易」，對股東及投資者有潛在重大影響。
重點摘要
- 董事會批准： 董事會允許最多人民幣25億元閒置資金作現金管理及理財產品投資。
- 交易詳情： 於2026年5月14日至26日，RemeGen與華泰證券（HTSC）簽訂九份協議，購買理財產品，總額為人民幣5.98億元。
- 產品資訊： 最新第九份協議投資人民幣6,000萬元於「紫金信託•固安新亮金1號集合資金信託計劃」，產品類型為固定收益集合信託，期限10年，設6個月鎖定期後可部分或全部贖回，風險評級為低至中等，收益高於銀行定期存款，但具市場波動性。
- 上市規則影響： 所有交易與同一金融機構（HTSC）及性質相似，12個月內需合併計算比例，已超過5%但低於25%，屬「須披露交易」，公司需按規則報告及公告。
對股東及股價敏感事項
- 資金運用： 公司擬善用閒置資金提升回報，董事認為條款公平合理並符合公司及全體股東利益。
- 風險控制： 強調投資風險可控，產品選擇低至中等風險、收益優於銀行定期。
- 透明度： 所有協議均屬公平磋商，HTSC及其主要股東為獨立第三方。
- 股價影響： 大額資金投入理財產品或影響流動性、風險狀況及資本結構，此舉可能成為股價敏感消息，亦反映公司財務狀況穩健及有信心提升資金回報，或正面影響投資者情緒。
協議摘要
- 2026年5月14日：協議1-4（人民幣6,000萬、7,500萬、1.02億、2.16億）
- 2026年5月19日：協議5-6（人民幣1,500萬、2,000萬）
- 2026年5月20日：協議7-8（人民幣2,000萬、3,000萬）
- 2026年5月26日：協議9（人民幣6,000萬）
重要定義
- 須披露交易： 按上市規則，交易規模超過公司資產5%需公告。
- 關聯人士： 按上市規則定義，HTSC確認為獨立第三方。
董事會組成
董事會包括執行董事、非執行董事及獨立非執行董事，由王衛東先生為主席。
結語
RemeGen積極運用閒置資金投資理財產品、嚴控風險及提升資金回報，此舉屬重大資本行動。累計交易已達須披露門檻，建議投資者密切關注公司流動性及風險管理，未來或影響盈利及股價。
免責聲明： 本文僅供資訊參考，不構成任何投資建議。投資者應自行研究及諮詢專業人士。所述資訊來自公開公告，或會隨時變更或解讀。
